汗腺膿瘍市場 - KOLの考察

当レポートでは、汗腺膿瘍市場について調査分析し、上市済みの治療法とパイプラインにある治療法に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

治療アルゴリズム

調査目的

上市済み/適応外の治療法

• 抗腫瘍壊死因子TNF製剤
  • Humira (adalimumab; AbbVie)
  • Remicade (infliximab; Janssen/Merck & Co.)

パイプライン治療法

• IL-17阻害薬
  • Cosentyx (secukinumab; Novartis)
  • Bimzelx (bimekizumab; UCB)
  • Izokibep (Acelyrin)
  • Sonelokimab (MoonLake Immunotherapeutics)
• IL-36阻害薬
  • Spevigo (spesolimab; Boehringer Ingelheim)
• JAK阻害薬
  • Povorcitinib (INCB54707; Incyte)
  • Jakafi/Jakavi (ruxolitinib; Incyte)
  • Rinvoq (upadacitinib; AbbVie)
• JAK/TYK阻害薬
  • Brepocitinib (Priovant/Pfizer)
• 補体C5a阻害薬
  • Vilobelimab (InflaRx) and avacopan (Tavneos; Amgen/Vifor Fresenius)
• PDE4阻害薬
  • Orismilast (UNION therapeutics)
• ケモカイン（CXCR1/2）阻害薬
  • LY3041658 (Lilly)
• IL-1阻害薬
  • Lutikizumab (ABT-981; AbbVie)
• その他の作用機序
  • 重要な考察のまとめ

HSの管理に向けた治療力学

• 重要な考察のまとめ
  • 複数の医薬品の承認により、HSに対するよりよい治療オプションがKOLにもたらされる：抗IL17療法はしっかりと確立される見込み

HS市場の見通しと進化

• 重要な考察のまとめ
  • 疾患の不均一性と遅い疾患の診断が、HSの治療における課題の一部を構成している

付録

KOLの速報

Expect significant and much needed expansion of therapy options in the HS treatment sector. Will Abbvie's Humira/biosimilar adalimumab maintain its first-line position? How do KOLs assess anti-IL17 drugs and why do they say that UCB's Bimzelx has an edge on Novartis' Cosentyx? Why are experts enthusiastic about oral JAK inhibitors, despite safety concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area:

• 21 Sep 2023 KOL Bulletin -- Views on top-line results from the Phase IIb/III trial of Acelyrin's izokibep in moderate-to-severe HS

Table of Contents

Executive summary (2)

Treatment algorithm (2)

Research objectives (1)

Marketed and off-label therapies (8)

• Anti-tumour necrosis factor TNF agents (8)
  • Humira (adalimumab; AbbVie) (8)
  • Remicade (infliximab; Janssen/Merck & Co.)

Pipeline therapies (47)

• IL-17 inhibitors (17)
  • Cosentyx (secukinumab; Novartis) (8)
  • Bimzelx (bimekizumab; UCB) (4)
  • Izokibep (Acelyrin) (3)
  • Sonelokimab (MoonLake Immunotherapeutics) (2)
• IL-36 inhibitors (1)
  • Spevigo (spesolimab; Boehringer Ingelheim) (1)
• JAK inhibitors (12)
  • Povorcitinib (INCB54707; Incyte) (6)
  • Jakafi/Jakavi (ruxolitinib; Incyte) (3)
  • Rinvoq (upadacitinib; AbbVie) (3)
• JAK/TYK inhibitor (1)
  • Brepocitinib (Priovant/Pfizer) (1)
• Complement C5a inhibitors (4)
  • Vilobelimab (InflaRx) and avacopan (Tavneos; Amgen/Vifor Fresenius) (4)
• PDE4 inhibitor (3)
  • Orismilast (UNION therapeutics) (3)
• Chemokine (CXCR1/2) inhibitor (3)
  • LY3041658 (Lilly) (3)
• IL-1 inhibitor (3)
  • Lutikizumab (ABT-981; AbbVie) (3)
• Other mechanisms of action (3)
  • Key insights summary (3)

Treatment dynamics for the management of HS

• Key insights summary
  • Multiple drug approvals will provide KOLs with better treatment options for HS: anti-IL17 therapies will become firmly established

Outlook and evolution of the HS market (1)

• Key insights summary (1)
  • Disease heterogeneity and late disease diagnosis comprise some of the challenges in the treatment of HS (1)

Appendix

• KOL details
  • KOLs from North America
  • KOLs from the Europe

KOL Bulletins (1)